189 related articles for article (PubMed ID: 34910788)
1. Bioinformatics analysis for the role of CALR in human cancers.
Li Y; Liu X; Chen H; Xie P; Ma R; He J; Zhang H
PLoS One; 2021; 16(12):e0261254. PubMed ID: 34910788
[TBL] [Abstract][Full Text] [Related]
2. Calreticulin as a prognostic biomarker and correlated with immune infiltrate in kidney renal clear cell carcinoma.
Sun M; Qi S; Wu M; Xia W; Xiong H
Front Genet; 2022; 13():909556. PubMed ID: 36338983
[No Abstract] [Full Text] [Related]
3. Integrated bioinformatic analysis of HNF1A in human cancers.
Zhang E; Huang X; He J
J Int Med Res; 2021 Mar; 49(3):300060521997326. PubMed ID: 33752475
[TBL] [Abstract][Full Text] [Related]
4. Calreticulin increases growth and progression of natural killer/T-cell lymphoma.
Zheng Y; Li C; Xin P; Peng Q; Zhang W; Liu S; Zhu X
Aging (Albany NY); 2020 Nov; 12(23):23822-23835. PubMed ID: 33221760
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive Transcriptomic Analysis Reveals the Role of the Immune Checkpoint HLA-G Molecule in Cancers.
Xu HH; Gan J; Xu DP; Li L; Yan WH
Front Immunol; 2021; 12():614773. PubMed ID: 34276642
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive Analysis of Fibroblast Growth Factor Receptor (FGFR) Family Genes in Breast Cancer by Integrating Online Databases and Bioinformatics.
Zhou Z; Wu B; Tang X; Ke R; Zou Q
Med Sci Monit; 2020 May; 26():e923517. PubMed ID: 32381997
[TBL] [Abstract][Full Text] [Related]
7. Differential expression and molecular interactions of chromosome region maintenance 1 and calreticulin exportins in breast cancer cells.
Cruz-Ramos E; Sandoval-Hernández A; Tecalco-Cruz AC
J Steroid Biochem Mol Biol; 2019 Jan; 185():7-16. PubMed ID: 29981820
[TBL] [Abstract][Full Text] [Related]
8. Correlation of expression levels of ANXA2, PGAM1, and CALR with glioma grade and prognosis.
Gao H; Yu B; Yan Y; Shen J; Zhao S; Zhu J; Qin W; Gao Y
J Neurosurg; 2013 Apr; 118(4):846-53. PubMed ID: 23082878
[TBL] [Abstract][Full Text] [Related]
9. Immunosuppression by Mutated Calreticulin Released from Malignant Cells.
Liu P; Zhao L; Loos F; Marty C; Xie W; Martins I; Lachkar S; Qu B; Waeckel-Énée E; Plo I; Vainchenker W; Perez F; Rodriguez D; López-Otin C; van Endert P; Zitvogel L; Kepp O; Kroemer G
Mol Cell; 2020 Feb; 77(4):748-760.e9. PubMed ID: 31785928
[TBL] [Abstract][Full Text] [Related]
10. Calreticulin and cancer.
Fucikova J; Spisek R; Kroemer G; Galluzzi L
Cell Res; 2021 Jan; 31(1):5-16. PubMed ID: 32733014
[TBL] [Abstract][Full Text] [Related]
11. Calreticulin Expression Controls Cellular Redox, Stemness, and Radiosensitivity to Function as a Novel Adjuvant for Radiotherapy in Neuroblastoma.
Chen CJ; Hu YC; Chien Y; Huang WC; Wu CS; Tsai CY; Lin YH; Lee MS; Chien CS; Yang YP; Lee MC; Tseng CC; Chi HC
Oxid Med Cell Longev; 2023; 2023():8753309. PubMed ID: 36644580
[TBL] [Abstract][Full Text] [Related]
12. Conformation sensitive gel electrophoresis for the detection of calreticulin mutations in BCR-ABL1-negative myeloproliferative neoplasms.
Zakaria NA; Rosle NA; Siti Asmaa MJ; Aziee S; Haiyuni MY; Samat NA; Husin A; Hassan R; Ramli M; Mohamed Yusoff S; Ibrahim IK; Al-Jamal HAN; Johan MF
Int J Lab Hematol; 2021 Dec; 43(6):1451-1457. PubMed ID: 34125992
[TBL] [Abstract][Full Text] [Related]
13. Surface-exposed and soluble calreticulin: conflicting biomarkers for cancer prognosis.
Kepp O; Liu P; Zhao L; Plo I; Kroemer G
Oncoimmunology; 2020 Jul; 9(1):1792037. PubMed ID: 32923154
[TBL] [Abstract][Full Text] [Related]
14. Calreticulin mutation specific CAL2 immunohistochemistry accurately identifies rare calreticulin mutations in myeloproliferative neoplasms.
Mózes R; Gángó A; Sulák A; Vida L; Reiniger L; Timár B; Krenács T; Alizadeh H; Masszi T; Gaál-Weisinger J; Demeter J; Csomor J; Matolcsy A; Kajtár B; Bödör C
Pathology; 2019 Apr; 51(3):301-307. PubMed ID: 30606612
[TBL] [Abstract][Full Text] [Related]
15. Calreticulin is crucial for calcium homeostasis mediated adaptation and survival of thick ascending limb of Henle's loop cells under osmotic stress.
Bibi A; Agarwal NK; Dihazi GH; Eltoweissy M; Van Nguyen P; Mueller GA; Dihazi H
Int J Biochem Cell Biol; 2011 Aug; 43(8):1187-97. PubMed ID: 21554974
[TBL] [Abstract][Full Text] [Related]
16. Driver mutations and prognosis in primary myelofibrosis: Mayo-Careggi MPN alliance study of 1,095 patients.
Tefferi A; Nicolosi M; Mudireddy M; Szuber N; Finke CM; Lasho TL; Hanson CA; Ketterling RP; Pardanani A; Gangat N; Mannarelli C; Fanelli T; Guglielmelli P; Vannucchi AM
Am J Hematol; 2018 Mar; 93(3):348-355. PubMed ID: 29164670
[TBL] [Abstract][Full Text] [Related]
17. Mutant specific anti calreticulin antibody (CAL2) immunohistochemistry as a screening test for calreticulin (CALR) mutation testing.
Rahman K; Chandra D; Singh MK; Gupta R; Sharma A; Paul P; Kumar S; Sharma S; Nityanand S
Int J Lab Hematol; 2020 Oct; 42(5):604-611. PubMed ID: 32463176
[TBL] [Abstract][Full Text] [Related]
18. Pancancer Analyses Reveal Genomics and Clinical Characteristics of the SETDB1 in Human Tumors.
Lin X; Xiao M; Chen Z; Ding C; Zhang T; Li Q
J Oncol; 2022; 2022():6115878. PubMed ID: 35656340
[TBL] [Abstract][Full Text] [Related]
19. Efficient induction of anti-tumor immune response in esophageal squamous cell carcinoma via dendritic cells expressing MAGE-A3 and CALR antigens.
Liu X; Song N; Liu Y; Liu Y; Li J; Ding J; Tong Z
Cell Immunol; 2015 Jun; 295(2):77-82. PubMed ID: 25863743
[TBL] [Abstract][Full Text] [Related]
20. Rare type 1-like and type 2-like calreticulin mutants induce similar myeloproliferative neoplasms as prevalent type 1 and 2 mutants in mice.
Toppaldoddi KR; da Costa Cacemiro M; Bluteau O; Panneau-Schmaltz B; Pioch A; Muller D; Villeval JL; Raslova H; Constantinescu SN; Plo I; Vainchenker W; Marty C
Oncogene; 2019 Mar; 38(10):1651-1660. PubMed ID: 30846848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]